Wakefield District Women's Health Leads

Case Study

Breast Cancer and Fezolinetant

National Institute for Health and Care Excellence


- •
- •
- \bullet

Patient:


A patient with a past medical history of breast cancer had read about Fezolinetant and has requested a prescription for hot flushes.

Background

- Fezolinetant was licensed by the MHRA in December 2023 for treating vasomotor symptoms.
- As a neurokinin 3 receptor antagonist, it works by influencing brain neurotransmitters that regulate vasomotor symptoms through the hypothalamic-pituitaryovarian axis.
- It is awaiting NICE appraisal, expected in May 2025, and is not yet classified by the West Yorkshire Area Prescribing Committee, making it unavailable for NHS prescription at this time.
- It is currently a RED drug pending



Outcome



 But also discussed the role of CBT – including Turning Points CBT for menopause support – patients can self refer

https://talking.turning-point.co.uk/



